{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"As per CSP Section 7.2, patient monitoring during treatment with open-label osimertinib is monitored by the investigator per local clinical guidance. Serious AEs and AESIs are reported in the eCRF but were not analyzed/tabulated at the time of primary analysis. Safety assessments are to be performed as per local clinical practice and not collected as part of study data capture in line with the protocol."},"pointOfContact":{"email":"information.center@astrazeneca.com","organization":"AstraZeneca Clinical Study Information Center","phone":"1-877-240-9479","title":"Global Clinical Lead"}}